PT - JOURNAL ARTICLE AU - Mick, Eran AU - Kamm, Jack AU - Pisco, Angela Oliveira AU - Ratnasiri, Kalani AU - Babik, Jennifer M. AU - Calfee, Carolyn S. AU - Castañeda, Gloria AU - DeRisi, Joseph L. AU - Detweiler, Angela AU - Hao, Samantha AU - Kangelaris, Kirsten N. AU - Kumar, G. Renuka AU - Li, Lucy M. AU - Mann, Sabrina A. AU - Neff, Norma AU - Prasad, Priya A. AU - Serpa, Paula Hayakawa AU - Shah, Sachin J. AU - Spottiswoode, Natasha AU - Tan, Michelle AU - Christenson, Stephanie A. AU - Kistler, Amy AU - Langelier, Charles TI - Upper airway gene expression differentiates COVID-19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2 AID - 10.1101/2020.05.18.20105171 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.18.20105171 4099 - http://medrxiv.org/content/early/2020/05/19/2020.05.18.20105171.short 4100 - http://medrxiv.org/content/early/2020/05/19/2020.05.18.20105171.full AB - We studied the host transcriptional response to SARS-CoV-2 by performing metagenomic sequencing of upper airway samples in 238 patients with COVID-19, other viral or non-viral acute respiratory illnesses (ARIs). Compared to other viral ARIs, COVID-19 was characterized by a diminished innate immune response, with reduced expression of genes involved in toll-like receptor and interleukin signaling, chemokine binding, neutrophil degranulation and interactions with lymphoid cells. Patients with COVID-19 also exhibited significantly reduced proportions of neutrophils and macrophages, and increased proportions of goblet, dendritic and B-cells, compared to other viral ARIs. Using machine learning, we built 26-, 10- and 3-gene classifiers that differentiated COVID-19 from other acute respiratory illnesses with AUCs of 0.980, 0.950 and 0.871, respectively. Classifier performance was stable at low viral loads, suggesting utility in settings where direct detection of viral nucleic acid may be unsuccessful. Taken together, our results illuminate unique aspects of the host transcriptional response to SARS-CoV-2 in comparison to other respiratory viruses and demonstrate the feasibility of COVID-19 diagnostics based on patient gene expression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative, and the National Heart, Lung, and Blood Institute (1K23HL138461-01A1).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGene counts, sample metadata, IDSeq reports and code for the DE analysis, cell type proportions analysis and COVID-19 gene expression classifiers are available on github.https://github.com/czbiohub/covid19-transcriptomics-pathogenesis-diagnostics-results